Zenas Biopharma, Common Etf Shares Owned By Institutions
| ZBIO Etf | USD 10.01 0.25 2.56% |
Zenas BioPharma, Common fundamentals help investors to digest information that contributes to Zenas BioPharma,'s financial success or failures. It also enables traders to predict the movement of Zenas Etf. The fundamental analysis module provides a way to measure Zenas BioPharma,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zenas BioPharma, etf.
Zenas |
Zenas BioPharma, Common ETF Shares Owned By Institutions Analysis
Zenas BioPharma,'s Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of Zenas BioPharma, Common are shares owned by institutions. This indicator is about the same for the Biotechnology average (which is currently at 0.0) family and about the same as Health Care (which currently averages 0.0) category. This indicator is about the same for all United States etfs average (which is currently at 0.0).
Zenas Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zenas BioPharma,'s direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Zenas BioPharma, could also be used in its relative valuation, which is a method of valuing Zenas BioPharma, by comparing valuation metrics of similar companies.Zenas BioPharma, is currently under evaluation in shares owned by institutions as compared to similar ETFs.
Fund Asset Allocation for Zenas BioPharma,
The fund invests most of its assets under management in various types of exotic instruments, with the rest of asset invested in stocks.Asset allocation divides Zenas BioPharma,'s investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Zenas Fundamentals
| EBITDA | (56.31 M) | ||||
| Net Income | (37.12 M) | ||||
| Total Debt | 293.9 M | ||||
| Book Value Per Share | (21.07) X | ||||
| Cash Flow From Operations | (30.53 M) | ||||
| Earnings Per Share | (3.90) X | ||||
| Beta | -2.35 | ||||
| Market Capitalization | 673.29 M | ||||
| Total Asset | 68.18 M | ||||
| Retained Earnings | (230.4 M) | ||||
| Working Capital | 36.55 M | ||||
| One Year Return | (24.31) % | ||||
| Three Year Return | (33.04) % | ||||
| Net Asset | 68.18 M | ||||
| Last Dividend Paid | 0.002 | ||||
| Equity Positions Weight | 20.01 % |
About Zenas BioPharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zenas BioPharma, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zenas BioPharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zenas BioPharma, Common based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Zenas BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zenas BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with Zenas Etf
Moving against Zenas Etf
| 0.81 | VAXX | Vaxxinity | PairCorr |
| 0.7 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.69 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.64 | CEROW | CERo Therapeutics Symbol Change | PairCorr |
| 0.58 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
The ability to find closely correlated positions to Zenas BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zenas BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zenas BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zenas BioPharma, Common to buy it.
The correlation of Zenas BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zenas BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zenas BioPharma, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zenas BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.